Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy

Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of...

Full description

Saved in:
Bibliographic Details
Published in:Medical hypotheses 2017-06, Vol.103, p.32-34
Main Authors: Aragon-Martinez, Othoniel H, Martinez-Morales, Flavio, Isiordia-Espinoza, Mario A, Luque Contreras, Diana, Zapata Morales, Juan R, Gonzalez-Rivera, Maria L
Format: Article
Language:English
Subjects:
Adenosine Triphosphate - metabolism
Anti-Bacterial Agents - therapeutic use
Antioxidants - metabolism
Area Under Curve
Bacterial Infections - complications
Bacterial Infections - drug therapy
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Diabetes Complications - drug therapy
Diabetes Mellitus - drug therapy
Drug Resistance, Bacterial
Fluoroquinolones - therapeutic use
Humans
Internal Medicine
Models, Theoretical
Oxidative Stress
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of drugs. Patients with diabetes and/or cardiovascular diseases present abnormal levels of oxidative stress in the blood stream. In this regards, our hypothesis supposes that patients with diabetes and/or cardiovascular disease suffering a bacterial disease could experience a therapeutic failure and bacterial resistance when treated with fluoroquinolones. The crucial mechanism could be an inefficient blood distribution of the drug via red blood cell dysfunction induced by oxidative stress that might reduce the pharmacokinetic-pharmacodinamic ratios. In this way, we review the scientific information to support our hypothesis alongside possible implications. Additionally, this work exhibits the urgent need of studies considering these conditions for quinolone agents.
ISSN:0306-9877
1532-2777
DOI:10.1016/j.mehy.2017.04.004